Fortrea (NASDAQ:FTRE) Price Target Lowered to $16.00 at Robert W. Baird

Fortrea (NASDAQ:FTRE) had its price objective decreased by investment analysts at Robert W. Baird from $19.00 to $16.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 48.15% from the stock’s current price.

A number of other research analysts also recently commented on FTRE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fortrea in a report on Thursday, January 22nd. Mizuho set a $15.00 target price on shares of Fortrea in a report on Friday, January 9th. Truist Financial set a $22.00 price objective on shares of Fortrea and gave the company a “buy” rating in a research report on Thursday, January 8th. TD Cowen raised their target price on shares of Fortrea from $7.00 to $15.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Finally, Citigroup raised Fortrea from a “neutral” rating to a “buy” rating and upped their target price for the company from $12.00 to $21.00 in a report on Thursday, December 11th. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.45.

Fortrea Stock Performance

Fortrea stock opened at $10.80 on Friday. Fortrea has a 52 week low of $3.97 and a 52 week high of $18.67. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.81. The stock has a market cap of $997.92 million, a P/E ratio of -0.96, a price-to-earnings-growth ratio of 0.30 and a beta of 1.59. The stock has a 50 day moving average of $15.28 and a 200-day moving average of $12.28.

Fortrea (NASDAQ:FTRE) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.07). Fortrea had a negative net margin of 36.77% and a positive return on equity of 5.64%. The company had revenue of $660.50 million during the quarter, compared to analyst estimates of $665.22 million. On average, analysts expect that Fortrea will post 0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Fortrea

A number of hedge funds have recently made changes to their positions in FTRE. Vanguard Group Inc. grew its holdings in Fortrea by 3.2% in the 4th quarter. Vanguard Group Inc. now owns 8,331,016 shares of the company’s stock worth $143,710,000 after buying an additional 258,098 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Fortrea by 3.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 8,272,597 shares of the company’s stock worth $142,702,000 after acquiring an additional 293,992 shares during the period. AQR Capital Management LLC grew its stake in shares of Fortrea by 494.8% in the second quarter. AQR Capital Management LLC now owns 6,515,124 shares of the company’s stock worth $31,729,000 after purchasing an additional 5,419,842 shares in the last quarter. State Street Corp increased its holdings in shares of Fortrea by 1.0% during the fourth quarter. State Street Corp now owns 4,110,899 shares of the company’s stock valued at $70,913,000 after purchasing an additional 39,777 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Fortrea by 21.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,219,029 shares of the company’s stock valued at $55,528,000 after purchasing an additional 565,891 shares during the period.

More Fortrea News

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management says full‑year revenue and adjusted EBITDA results were delivered in line with stated targets, and full‑year cost savings exceeded previously communicated goals. GlobeNewswire Release
• Neutral Sentiment: Company posted its earnings materials and conference call slide deck (useful for investors evaluating segment performance, backlog and margin drivers). MarketBeat Earnings/Slide Deck
• Neutral Sentiment: Earnings call transcripts are available for additional color on client demand trends and cost‑takeout timing. Yahoo Transcript
• Negative Sentiment: Q4 EPS of $0.09 missed the Zacks/consensus estimate of $0.16, a notable earnings shortfall versus analyst expectations. Zacks: Earnings Lag Estimates
• Negative Sentiment: Q4 revenue of $660.5M slightly missed consensus (~$665.2M), a modest top‑line shortfall that weighed on near‑term sentiment. Yahoo: Sales Below Estimates
• Negative Sentiment: FY2026 revenue guidance was set at $2.6–$2.7B, which sits at or slightly below consensus — investors may view the midpoint/low end as conservative given recent expectations. GlobeNewswire Guidance

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.